周素芽　刘伟光杭州市儿童医院新生儿科，浙江杭州　310014

匹多莫德对支原体肺炎患儿免疫功能及炎性因子的影响

周素芽刘伟光
杭州市儿童医院新生儿科，浙江杭州310014

目的 观察匹多莫德对支原体肺炎患儿免疫功能及炎性因子的影响。方法 研究对象为2013年5月～2015年5月在我院就诊的支原体肺炎患儿共100例，所有患儿根据治疗方法不同分为观察组和对照组，每组各50例，两组均予退热、止咳、解痉等治疗，对照组予阿奇霉素，观察组加用匹多莫德口服液。比较两组治疗后的临床疗效及两组治疗前后临床症状积分的变化情况，并检测两组患者治疗前后免疫功能及炎症因子的变化情况。结果 观察组总有效率为96.00%，明显高于对照组的78.00%，两组总有效率组间比较，差异有统计学意义（P＜0.05）。观察组的临床症状积分显著低于对照组，差异有统计学意义（P＜0.05）。观察组和对照组治疗后CD4+、CD4+/CD8+分别较治疗前显著升高，且观察组治疗后CD4+、CD4+/CD8+的水平显著高于对照组。观察组和对照组治疗后IL-4、IL-6、IL-10分别较治疗前显著降低，且观察组治疗后IL-4、IL-6、IL-10水平显著低于对照组（P＜0.05）。结论匹多莫德可以提高支原体肺炎的疗效，提高免疫功能，抑制炎症反应，值得推广和应用。

支原体肺炎；匹多莫德；免疫功能；炎性因子

［Abstract］Objective To observe the influence of pidotimod on immunity and inflammatory factors in children with mycoplasma pneumonia.Methods A total of 100 children with mycoplasma pneumonia treated in our hospital from May 2013 to May 2015 were selected and divided into observation group（n=50）and control group（n=50）according to therapeutic methods.Patients in both groups were given treatment to bring down fever and relieve cough and spasm.Patients in the control group were given azithromycin，and patients in the observation group were additionally given pidotimod oral liquid for 4 weeks as a course of treatment.The clinical efficacy after treatment and the changes of clinical symptom scores before and after treatment were compared between two groups.The changes of immunity and inflammatory factors before and after treatment were detected in both groups.Results The overall response rate in the observation group was 96.00%，which was significantly higher than the 78.00%in the control group（P＜0.05）.The clinical symptom scores in the observation group were significantly lower than those in the control group（P＜0.05）.The levels of CD4+and CD4+/CD8+after treatment were significantly higher than those before treatment in both groups，and the levels of CD4+and CD4+/CD8+after treatment were significantly higher in the observation group than in the control group.The levels of IL-4，IL-6，and IL-10 after treatment were significantly lower than those before treatment in both groups，and the levels of IL-4，IL-6，and IL-10 after treatment were significantly lower in the observation group than in the control group（P＜0.05）.Conclusion Pidotimod can improve the efficacy on mycoplasma pneumonia，strengthen immunity，and inhibit inflammatory response，thus is worthy to be promoted.

［Key words］Mycoplasma pneumonia；Pidotimod；Immunity；Inflammatory factor

支原体肺炎（mycoplasmal pneumonia，MPP）是儿科的常见病、多发病，多发于5～15岁儿童，病情呈迁延不愈或反复发作。支原体肺炎多表现为炎性介质水平升高和免疫功能低下，近年来发病率也逐年增多，支原体肺炎急性发作时主要予以退热、氧疗、补液及镇静等对症治疗及抗生素、肺外并发症治疗，但传统临床治疗忽视了对患儿免疫功能的调节及改善［1-3］。……